三元生物(301206.SZ):“年產2萬噸阿洛酮糖項目”中的1萬噸產能已完成工程主體建設、設備安裝和調試工作
格隆匯7月8日丨三元生物(301206.SZ)公佈關於年產2萬噸阿洛酮糖項目部分產能(1萬噸)試生產暨項目進展公吿,近日公司實施的“年產2萬噸阿洛酮糖項目”中的1萬噸產能已完成工程主體建設、設備安裝和調試工作,公司將按照產品工藝、生產流程分階段安排試生產過程。後續公司將根據工藝情況,對設備裝置進行調整優化,逐步實現項目達產達標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.